Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activityBijl, M., Horst, G., Limburg, PC. & Kallenberg, CGM., 2001, In : Lupus. 10, 12, p. 866-872 7 p.
Research output: Contribution to journal › Article › Academic › peer-review
Levels of apoptotic lymphocytes have been found to be increased in SLE and persistence of apoptotic cells has been associated with autoantibody production, Increased lymphocyte Fas (CD95) expression due to lymphocyte activation may account for increased Susceptibility to Fas-mediated apoptosis in SLE.
Flowcytometry,as performed to evaluate membrane expression of Fas in combination with the activation markers CD25, HLA-DR and CD38 on, respectively, CD4(+), CD8(+) and CD19(+) lymphocytes of SLE patients with inactive (n=20) and with active disease (n=13). SLEDAI-scores were calculated. Healthy volunteers (n=14) served as controls.
Percentages of CD4(+) T-cells expressing CD25 and CD19(+) B-cells expressing CD38 were increased inpatients,kith active disease compared to controls (P=0.03. P=0.04. respectively). In contrast to CD4(+) and CD8(+) cells, percentage's of CD19(+) cells expressing Fas were increased in SLE patients with active disease (P=0.0002 vs controls). In these patients percentages of cells double positive for both CD38 and Fas were increased compared to patients with inactive disease (P=0.006) and controls (P=0.0007). Percentages of CD19(+) cells expressing Fas correlated with SLEDAI-scores.
In SLE patients, percentages of Fas-expressing B-lymphocytes are increased, are related to the state of lymphocyte activation, and correlate to disease activity. Increased Fas expression results in a higher susceptibility for Fas-mediated apoptosis, which might contribute to the increased levels of apoptotic lymphocytes in SLE patients.
|Number of pages||7|
|Publication status||Published - 2001|
- SLE, Fas, CD95, lymphocyte activation, apoptosis, DOUBLE-STRANDED DNA, SERUM-SOLUBLE FAS, IN-VITRO, APOPTOSIS, CELLS, LIGAND, AUTOANTIBODIES, INHIBITION, ANTIBODY, ANTIGEN